全球冠状病毒疫苗专利分析

doi:10.13523/j.cb.2002105

中国生物工程杂志

2020, Vol. 40

Issue (1-2): 57-64 DOI: 10.13523/j.cb.2002105

冠状病毒药物研发与技术情报专辑

全球冠状病毒疫苗专利分析

谢华玲,吕璐成,杨艳萍(

)

中国科学院文献情报中心北京 100190

Patent Analysis of Global Coronavirus Vaccine

XIE Hua-ling,LV Lu-cheng,YANG Yan-ping(

)

National Science Library, Chinese Academy of Science, Beijing 100190, China

全文: PDF(1190 KB) HTML

摘要：

冠状病毒是一类可感染人类和动物的RNA病毒,可引起严重急性呼吸综合征(SARS)和中东呼吸综合征(MERS)等严重疾病。新型冠状病毒是以前从未在人体中发现的冠状病毒新毒株,其人际传播迅速,引起了各国政府的高度重视并积极寻求疫苗防控对策。基于冠状病毒疫苗领域全景专利,在综合对比分析该领域的全部专利的发展趋势、主要国家和主要机构的专利产出的同时,重点揭示了其中的人用相关疫苗的发展与分布情况以及重点分析了人用疫苗产品的研发现状,以期为我国冠状病毒疫苗领域的科研工作者和管理决策者提供参考数据。

关键词： 冠状病毒; SARS-CoV-2; COVID-19 疫苗; 人用疫苗; 专利分析

Abstract:

Coronavirus is a kind of RNA virus which can infect human and animals. Coronavirus can cause severe diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The coronavirus (SARS-CoV-2) is a new strain which has never been found in human body before. The rapid transmission of SARS-CoV-2 has aroused the attention of governments all over the world and actively sought for vaccines. This report based on the panoramic patent in the field of coronavirus vaccine, comprehensively analyzed the development trend of patents, the output of major countries and institutions. At the same time, the report focuses on revealing the development and distribution of human related vaccines, as well as the research and development status of human related vaccine products. The report aims to provide references and implications for scientific researchers and decision makers in the field of Coronavirus Vaccine.

Key words: Coronavirus SARS-CoV-2 COVID-19 Vaccine Human related vaccines Patent analysis

收稿日期: 2020-02-09 出版日期: 2020-03-27

ZTFLH:

Q819

通讯作者: 杨艳萍 E-mail: yangyp@mail.las.ac.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谢华玲
	吕璐成
	杨艳萍

引用本文:

谢华玲,吕璐成,杨艳萍. 全球冠状病毒疫苗专利分析[J]. 中国生物工程杂志, 2020, 40(1-2): 57-64.

XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine. China Biotechnology, 2020, 40(1-2): 57-64.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2002105 或 https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I1-2/57

图1 全球及中国冠状病毒疫苗专利公开趋势

图2 冠状病毒疫苗专利技术来源国家和地区分布

图3 冠状病毒疫苗主要国际专利申请机构

图4 冠状病毒疫苗主要国内专利申请机构

图5 人用疫苗-病毒分布分析

表1 冠状病毒疫苗四方专利信息

药物名称	针对疾病	研发机构	研发阶段
mRNA vaccine (2019 Chinese coronavirus infection)	2019 Chinese CoV infection	ModeRNA Therapeutics	Discovery
INO-4800	2019 Chinese CoV infection	Inovio Pharmaceuticals Inc	Discovery
GreMERSfi	MERS	Greffex Inc	Discovery
MERS-CoV recombinant vaccine (nanoparticle formulation)	MERS	Novavax Inc	No Development Reported
MERS-CoV vaccine	MERS	Baylor College of Medicine	No Development Reported
MERS-rabies dual vaccine	MERS	Thomas Jefferson University	No Development Reported
MERS Cov vaccine (recombinant viral vector)	MERS	The Jenner Institute	Phase I Clinical
MVA-MERS-S	MERS	Ludwig-Maximilians University of Munich	Phase I Clinical
BVRS-GamVac-Combi	MERS	Gamalei Institute of Epidemiology and Microbiology	Phase II Clinical
INO-4700	MERS	Inovio Pharmaceuticals Inc	Phase II Clinical
ChAdOx1 MERS	MERS	Vaccitech Ltd./University of Oxford	Phase I
GLS-5300	MERS	Inovio Pharmaceuticals/GeneOne Life Science	Phase I/II
Convalescent plasma	MERS	King Abdullah International Med Res Cent	Phase II
MERS-CoV vaccine	MERS	National Institute of Allergy and Infectious Diseases	Preclinical
MERS-Corona virus vaccine (recombinant live-attenuated measles virus vector)	MERS	Themis Bioscience GmbH	Preclinical
MERS-Cov vaccine	MERS	Institute of Microbiology, CAS	Preclinical
GREVAX/MERS	MERS	Greffex	Preclinical
MVA-MERS-S DF1	MERS	Universitaetsklinikum Hamburg- Eppendorf	Preclinical
SARS vaccine (delipidated)	SARS	Lipid Sciences Inc	Discontinued
SARS virus vaccine (adenoviral vector	SARS	GenPhar Inc	Discontinued
VRC-SRSDNA015-00-VP	SARS	National Institutes of Health	Discontinued
SARS vaccine (SimVec)	SARS	Genecure LLC	Discovery
SARS vaccine	SARS	Protein Potential LLC	Discovery
horse anti-SARS-CoV immunoglobulin	SARS	National Vaccine and Serum Institute	No Development Reported
SARS coronavirus vaccine	SARS	Chiron Corp	No Development Reported
adenovector-based vaccine (SARS coronavirus)	SARS	National Institute of Allergy and Infectious Diseases	No Development Reported
spike and nucleocapsid protein-targeting vaccine (SARS)	SARS	Shanghai Genomics Inc	No Development Reported
SARS-CoV recombinant vaccine (nanoparticle)	SARS	Novavax Inc	No Development Reported
SARS vaccine	SARS	Crucell Switzerland AG	No Development Reported
SARS vaccine (inactivated virus)	SARS	Sanofi Pasteur	No Development Reported
RBD-S SARS vaccine (SARS)	SARS	Baylor College of Medicine	No Development Reported
SARS vaccine (intramuscular	SARS	Shanghai TenGen Biomedical Co Ltd	No Development Reported
SARS DNA vaccine (li protein immunoregulating)	SARS	Antigen Express Inc	No Development Reported
influenza/SARS vaccine (deINS1 vector)	SARS	AVIR Green Hills Biotechnology AG	No Development Reported
PVI-3000	SARS	PeptiVir Inc	No Development Reported
D-3252	SARS	Protein Sciences Corp	No Development Reported
universal influenza vaccine (influenza/ SARS/coronavirus infection)	SARS	University of Colorado System	Outlicensed
enveloped virus vaccine (influenza/ SARS/coronavirus infection)	SARS	University of Colorado System	Outlicensed
SARS vaccine (VEE vector)	SARS	AlphaVax Inc	Preclinical
SARS coronavirus vaccine	SARS	Sinovac Biotech Ltd	Suspended
recombinant coronavirus vaccine	其他	IBAkteriaSp z oo	Discovery
MVA-S	其他	UniversitatAutonoma de Barcelona	No Development Reported

表2 冠状病毒疫苗的临床前和临床研究进展

[1]	Gorbalenya A E, Enjuanes L, Ziebuhr J , et al. Nidovirales: evolving the largest RNA virus genome. Virus Res, 2006,117, 17-37.
[2]	ScienceDaily. Study: Pig virus is easily transmitted among chickens and turkeys.[2020-02-09]. https://www.sciencedaily.com/releases/2020/01/200115130430.htm.
[3]	CEPI. CEPI to fund three programmes to develop vaccines against the novel coronavirus, nCoV-2019.[2020-02-09]. https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/.
[4]	CNBC. Moderna working with the NIH on coronavirus vaccine.[2020-02-09]. https://www.cnbc.com/video/2020/01/27/moderna-working-with-the-nih-on-coronavirus-vaccine.html.
[5]	GSK. CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus. [2020-02-09]. https://www.gsk.com/en-gb/media/press-releases/cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus/.
[6]	Song Z, Xu Y, Bao L , et al. Pub crosstef From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses, 2019,11(1):E59.
[7]	Zhang N, Tang J, Lu L , et al. Receptorbinding domain-based subunit vaccines against MERS-CoV. Virus Res, 2015,202:151.
[8]	Schindewolf C, Menachery V . Middle East respiratory syndrome vaccine candidates: Cautious optimism. Viruses, 2019,11(1):E74.
[9]	Cho H, Excler J L, Kim J H , et al. Development of Middle East respiratory syndrome coronavirus vaccines - Advances and challenges. Hum Vaccin Immunother, 2018,14(2):304.
[10]	Li F, Du L Y . MERS coronavirus: An emerging zoonotic virus. Viruses, 2019,11(7):E663.

[1]	贠涛,巩玥,谷芃,徐冰冰,李瑾,赵洗尘. 中国与“一带一路”参与国家抗击新冠肺炎疫情的国际科技合作现状与展望[J]. 中国生物工程杂志, 2021, 41(7): 110-121.
[2]	史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展^*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[3]	张赛,王刚,刘仲明,李辉军,汪大明,钱纯亘. 新型冠状病毒胶体金抗原快速检测试剂的研制及性能评价^*[J]. 中国生物工程杂志, 2021, 41(5): 27-34.
[4]	陈莹,李谦. 特殊酵母工业应用专利发展态势分析[J]. 中国生物工程杂志, 2021, 41(4): 91-99.
[5]	范月蕾,王跃,王恒哲,李丹丹,毛开云. 新型冠状病毒体外诊断技术研发现状与展望 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 150-161.
[6]	张赛,向乐,李林海,李辉军,王刚,钱纯亘. 新型冠状病毒(2019-nCoV)IgM /IgG抗体检测试剂的研制及性能评价[J]. 中国生物工程杂志, 2020, 40(8): 1-9.
[7]	蒋甜,张超,刘会洲. 微生物燃料电池发展态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 189-197.
[8]	巩玥,廖青云,于倩倩,史志祥,陈菁,张宇辉,赵光慧. 冠状病毒研究态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 21-37.
[9]	潘彤彤,陈永平. 重型/危重型新型冠状病毒肺炎关键治疗技术研究进展[J]. 中国生物工程杂志, 2020, 40(1-2): 78-83.
[10]	赵萍,杨艳萍. 人冠状病毒感染诊断技术专利态势分析[J]. 中国生物工程杂志, 2020, 40(1-2): 51-56.
[11]	李东巧,吕璐成,杨艳萍. 全球人冠状病毒抗体领域研发现状与发展趋势[J]. 中国生物工程杂志, 2020, 40(1-2): 65-70.
[12]	程永庆,刘金毅,林福玉,童梅. 重组人干扰素α1b与新型冠状病毒肺炎防治[J]. 中国生物工程杂志, 2020, 40(1-2): 71-77.
[13]	黄鹏飞,陈赟,陆娇,毛开云,袁银池. *生物医药专利密集型产业发展现状及建议^——以上海市为例**[J]. 中国生物工程杂志, 2020, 40(12): 108-116.
[14]	王国强,于茵茵,曾华辉,王旭东,吴玉彬,尚立芝,李玉林,张怡青,张西西,张振强,王云龙. 基于MS2噬菌体病毒样颗粒的RT-PCR检测新型冠状病毒(SARS-CoV-2)质控品制备^*[J]. 中国生物工程杂志, 2020, 40(12): 31-40.
[15]	廖小艳,陈丽丽. COVID-19疫苗研究现状^*[J]. 中国生物工程杂志, 2020, 40(12): 8-17.

Viewed

Full text

Abstract

Cited

Shared

Discussed